Research On GYBYS Performance Evaluation Based On BSC

At present,the material standard of living is constantly improving,people's health awareness is also significantly enhanced,and the attention of the pharmaceutical market continues to heat up.Under the influence of national policies and market competition,the internal structure of pharmaceutical enterprises is undergoing differentiation and adjustment,and the industry as a whole begins to shift gears.In this situation,the performance evaluation after merger and acquisition has become a subject that all pharmaceutical enterprises preparing for or having completed merger and acquisition must face.How to measure the performance of m & a comprehensively and reasonably,enhance the comprehensive strength of the enterprise through performance evaluation,and achieve the goal of M&A is more worthy of in-depth exploration.In view of this,this paper takes GYBYS,a typical representative of China's pharmaceutical mergers and acquisitions,as the research object,conducts a detailed study on the post-merger performance evaluation system of enterprises,and attempts to provide some reference and inspiration for other pharmaceutical enterprises in China who want to merge or complete mergers and acquisitions in the construction of the performance evaluation system of mergers and acquisitions.Through the comparison and analysis of traditional methods of enterprise performance evaluation,it is found that the balanced scorecard can more comprehensively evaluate the performance of enterprises.Therefore,it is decided to choose the perspective of the balanced scorecard to construct the performance evaluation system of GYBYS M&A.In the specific research link,firstly make an overview of both sides of the merger and acquisition process,and analyze the problems and causes of the case enterprise performance evaluation,and demonstrate the necessity and feasibility of applying the balanced scorecard.Then,through SWOT analysis and strategic map drawing,the strategic framework of GYBYS was sorted out from the four dimensions of BSC finance,customer,internal process,learning and growth,and then the exact indicators of the performance evaluation system were defined accordingly.At the same time,the method of combination weighting is adopted to determine the index weight.First,the analytic hierarchy process is used to calculate the subjective weight that can reflect the subjective intention.Then,the entropy method is used to calculate the objective weight with strong objectivity.Then,the evaluation of performance scores is standardized,and the performance evaluation system constructed is used to score the performance of GYBYS from 2013 to 2015,and the scoring results are compared with the performance before the merger and a detailed analysis is made.Finally,in order to better implement the performance rating system,put forward the corresponding safeguard measures.The main conclusions of the study are as follows: 1.The balanced scorecard method is conducive to improve the one-sidedness of traditional performance evaluation,which is mainly based on financial indicators.2.The application of combined weighting method combines the advantages of subjective and objective weighting method,which is conducive to improving the accuracy of the performance evaluation system of pharmaceutical M&A enterprises and making the evaluation results more scientific and reasonable.3.GYBYS overall performance improved significantly after the merger and acquisition,and the merger and acquisition activities were relatively successful,but the internal process dimension performance was slightly deficient,which needs to be paid attention to and improved.